Abstract
Anabolic androgenic steroids (AAS) are some of the most common performance enhancing drugs (PED) among society. Despite the broad spectrum of adverse effects and legal consequences, AAS are illicitly marketed and distributed in many countries. To circumvent existing laws, the chemical structure of AAS is modified and these designer steroids are sold as nutritional supplements mainly over the Internet. Several side effects are linked with AAS abuse. Only little is known about the pharmacological effects and metabolism of unapproved steroids due to the absence of clinical studies. The large number of designer steroid findings in dietary supplements and the detection of new compounds combined with legal loopholes for their distribution in many countries show that stricter regulations and better information policy are needed.
Keywords: AAS, designer steroids, dietary supplements, performance enhancing drugs.
Current Neuropharmacology
Title:Synthetic Androgens as Designer Supplements
Volume: 13 Issue: 1
Author(s): Jan Felix Joseph and Maria Kristina Parr
Affiliation:
Keywords: AAS, designer steroids, dietary supplements, performance enhancing drugs.
Abstract: Anabolic androgenic steroids (AAS) are some of the most common performance enhancing drugs (PED) among society. Despite the broad spectrum of adverse effects and legal consequences, AAS are illicitly marketed and distributed in many countries. To circumvent existing laws, the chemical structure of AAS is modified and these designer steroids are sold as nutritional supplements mainly over the Internet. Several side effects are linked with AAS abuse. Only little is known about the pharmacological effects and metabolism of unapproved steroids due to the absence of clinical studies. The large number of designer steroid findings in dietary supplements and the detection of new compounds combined with legal loopholes for their distribution in many countries show that stricter regulations and better information policy are needed.
Export Options
About this article
Cite this article as:
Joseph Felix Jan and Parr Kristina Maria, Synthetic Androgens as Designer Supplements, Current Neuropharmacology 2015; 13 (1) . https://dx.doi.org/10.2174/1570159X13666141210224756
DOI https://dx.doi.org/10.2174/1570159X13666141210224756 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Current Topics in Medicinal Chemistry Biomarkers, Critical Disease Pathways, Drug Targets, and Alternative Medicine in Male Breast Cancer
Current Drug Targets Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs
Current Cancer Therapy Reviews uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Physiological/Pathophysiological Significance of Vitamin D in Cancer, Cardiovascular Disorders and Beyond
Current Drug Metabolism FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Therapeutic Exploitation of Endogenous Anti-Inflammatory Mechanisms:Old and New Leads
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery